The FDA and Aduhelm: WTF?
World of DTC Marketing
JUNE 23, 2021
SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. sales alone, which is above consensus estimates of around $7 billion to $8 billion, the team said. Natalie Shure, The New Republic.
Let's personalize your content